BrainQ is transforming neurorehabilitation with a cloud-based, AI-powered device designed for in-home use. By emitting non-invasive, frequency-tuned extremely low frequency and low intensity electromagnetic fields (ELF-EMF), the technology promotes neurological recovery in the central nervous system. Tailored to each patient through advanced AI, BrainQ offers a groundbreaking solution for the more than one billion people worldwide living with neurodisorders, easing the burden of long-term treatment on both patients and their families. 

Why we invested?

Neurological disorders impact more than one billion people globally, with stroke ranking among the leading causes of death and adult disability. BrainQ is a first mover in this space, developing a breakthrough solution with broad applications well beyond existing stroke care technologies. With FDA approval for expedited market access and strong evidence of superior efficacy in reducing disability, BrainQ is positioned to address a market nearly 10x larger than current solutions. 

In the Founder’s Words

“I could immediately see that the first thing that Hanaco looks at and cares about is the founder—not just the numbers. Coming from the intersection of life science and technology, investors are generally obsessed with data. When I met Hanaco, the first thing I saw was that they cared about my vision, my aspirations, my leadership skills, my ability to run the company, and how I see its future. This meant a lot because it’s so rare in my world. The other thing I really love about Hanaco is how humble they are. Hanaco trusts you to do your job. They invested in you because of you. They are partners and advisers. They help you wherever you need it, but it’s your journey and they respect your decisions. ” — Yotam Drechsler, Founder, BrainQ